DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

September 23, 2011 15:05 ET

DiaMedica Inc. Announces Results of Annual and Special General Meeting

WINNIPEG, MANITOBA--(Marketwire - Sept. 23, 2011) - DiaMedica Inc. ("DiaMedica") (TSX VENTURE:DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual and Special General Meeting (the "AGM") of shareholders of DiaMedica dated September 22, 2011 David Allan, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were elected as the board of directors of the Corporation.

In addition to the election of directors, the shareholders passed all resolutions placed before them as outlined in the management information circular dated August 25, 2011, including the re-appointment of KPMG LLP, Chartered Accounts, as auditors for the upcoming year, the adoption of a shareholder rights plan, the adoption of an amended and restated stock option plan, and the adoption of a deferred share unit plan.

About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic compounds aimed to improve the lives of patients with diabetes and other major, medically unmet diseases. DiaMedica's lead compound, DM-199, represents a novel approach to treating Type 1 and Type 2 diabetes by demonstrating significant results against three major aspects of these diseases: 1) halting the autoimmune attack on beta cells; 2) proliferating insulin producing beta cells and 3) improving glucose control.

DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the enzyme glycogen synthase kinase. In preclinical studies, DM-204 significantly improved glucose control and decreased blood pressure.

The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.

Contact Information